Results 131 to 140 of about 202,126 (199)

The No-reflow Phenomenon: Is it Predictable by Demographic factors and Routine Laboratory Data? [PDF]

Acta Biomed, 2021
Namazi M, Mahmoudi E, Safi M, Jenab Y, Vakili H, Saadat H, Alipour Parsa S, Khaheshi I, Talasaz AH, Hosseini SH, Tabary M, Poorhosseini H.   +11 more
europepmc   +1 more source

Impact of intracoronary adenosine on the no-reflow phenomenon: A randomized, triple-blind, placebo-controlled clinical trial. [PDF]

Am Heart J Plus
Baharvand F, Aghajankhah M, Parvaneh S, Chaboki BG, Di Muro FM.   +4 more
europepmc   +1 more source

A Narrative Review of the Classical and Modern Diagnostic Methods of the No-Reflow Phenomenon. [PDF]

Diagnostics (Basel), 2022
Pantea-Roșan LR, Bungau SG, Radu AF, Pantea VA, Moisi MI, Vesa CM, Behl T, Nechifor AC, Babes EE, Stoicescu M, Gitea D, Iovanovici DC, Bustea C.   +12 more
europepmc   +1 more source

Association between the no-reflow phenomenon and clinical outcomes after endovascular treatment for acute ischemic stroke: A systematic review and meta-analysis. [PDF]

Eur Stroke J
Pereira da Silva AM, Ribeiro Gonçalves O, Falcão L, Ribeiro FV, Han ML, Rodrigues Menezes I, Honorato de Farias E, Loiola J, Marinheiro G, Noleto GS, Kaesmacher J, Mujanovic A, Günkan A.   +12 more
europepmc   +1 more source

Predictive Value of High-Sensitivity CRP Level on the No-Reflow Phenomenon in STEMI Patients. [PDF]

Cardiol Res Pract
Krasniqi X, Vincelj J, Koçinaj D, Berisha B, Bakalli A.   +4 more
europepmc   +1 more source

The "no-reflow" phenomenon in the coronary arteries

Arquivos Brasileiros de Cardiologia, 1999
Antônio Esteves Fº, Donaldo Pereira Garcia, Eulógio Emílio Martinez Fº   +2 more
doaj   +1 more source

Intracoronary adrenaline for the treatment of refractory no-reflow phenomenon: A single-centre experience. [PDF]

Cardiol J
Desperak P, Osuch M, Madowicz J, Małyszek-Tumidajewicz J, Wojtynek E, Hawranek M.   +5 more
europepmc   +1 more source

Effect of empagliflozin on reducing the no-reflow phenomenon in patients with ST-elevation myocardial infarction: rationale and design of the EMPA-PCI trial. [PDF]

Eur Heart J Open
Solis-Jimenez F, Araiza-Garaygordobil D, Masso-Bueso JS, Villalobos-Ordaz A, Arellano-Juvera F, Arredondo-Aragon F, Melendez-Ramirez G, Valdez-Ortiz R, Alday-Ramirez SM, Rodriguez-Zanella HG, Amezcua Guerra LM, Arias-Mendoza MA, Martinez-Rios MA, Arias-Sánchez EA, Eid-Lidt G.   +14 more
europepmc   +1 more source

Neutrophil Percentage/Albumin Ratio as an Independent Predictor of the No-Reflow Phenomenon in Patients with ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. [PDF]

Diagnostics (Basel)
Yavcin O, Yilmaz Y.
europepmc   +1 more source

Reduced adenosine receptor expression in ACS patients with no-reflow phenomenon undergoing primary PCI. [PDF]

Future Cardiol
Bagheri A, Alipour Parsa S, Namazi MH, Khaheshi I, Sohrabifar N.   +4 more
europepmc   +1 more source